JP7023876B2 - α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置 - Google Patents

α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置 Download PDF

Info

Publication number
JP7023876B2
JP7023876B2 JP2018568186A JP2018568186A JP7023876B2 JP 7023876 B2 JP7023876 B2 JP 7023876B2 JP 2018568186 A JP2018568186 A JP 2018568186A JP 2018568186 A JP2018568186 A JP 2018568186A JP 7023876 B2 JP7023876 B2 JP 7023876B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
group
acceptable salt
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509340A (ja
Inventor
クック，ジェームズ・エム
リー，グワングワン
ポー，マイケル・ミーン－ジン
サヴィッチ，ミロスラフ・エム
シビル，エティエンヌ
Original Assignee
ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド
センター フォー アディクション アンド メンタル ヘルス
ユニバーシティ・オブ・ベオグラード－ファカルティ・オブ・ファーマシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド, センター フォー アディクション アンド メンタル ヘルス, ユニバーシティ・オブ・ベオグラード－ファカルティ・オブ・ファーマシー filed Critical ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド
Publication of JP2019509340A publication Critical patent/JP2019509340A/ja
Priority to JP2022017827A priority Critical patent/JP7515526B2/ja
Application granted granted Critical
Publication of JP7023876B2 publication Critical patent/JP7023876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2018568186A 2016-03-18 2017-03-20 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置 Active JP7023876B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022017827A JP7515526B2 (ja) 2016-03-18 2022-02-08 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310409P 2016-03-18 2016-03-18
US62/310,409 2016-03-18
PCT/US2017/023206 WO2017161370A1 (en) 2016-03-18 2017-03-20 Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017827A Division JP7515526B2 (ja) 2016-03-18 2022-02-08 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Publications (2)

Publication Number Publication Date
JP2019509340A JP2019509340A (ja) 2019-04-04
JP7023876B2 true JP7023876B2 (ja) 2022-02-22

Family

ID=59851645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018568186A Active JP7023876B2 (ja) 2016-03-18 2017-03-20 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
JP2022017827A Active JP7515526B2 (ja) 2016-03-18 2022-02-08 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022017827A Active JP7515526B2 (ja) 2016-03-18 2022-02-08 α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置

Country Status (17)

Country Link
US (4) US10906909B2 (enExample)
EP (2) EP4129297A1 (enExample)
JP (2) JP7023876B2 (enExample)
AU (2) AU2017235665B2 (enExample)
CA (1) CA3016491A1 (enExample)
CY (1) CY1125576T1 (enExample)
DK (1) DK3439665T3 (enExample)
ES (1) ES2926918T3 (enExample)
HR (1) HRP20221098T1 (enExample)
HU (1) HUE059774T2 (enExample)
LT (1) LT3439665T (enExample)
PL (1) PL3439665T3 (enExample)
PT (1) PT3439665T (enExample)
RS (1) RS63674B1 (enExample)
SI (1) SI3439665T1 (enExample)
SM (1) SMT202200372T1 (enExample)
WO (1) WO2017161370A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US12636291B2 (en) * 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
JP2024533306A (ja) * 2021-09-08 2024-09-12 ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド 認知および気分症状の処置のためのイミダゾベンゾジアゼピン
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023059443A1 (en) * 2021-10-07 2023-04-13 Pantherics Incorporated Methods and compounds for treating inflammation
US20260125388A1 (en) * 2022-10-04 2026-05-07 Uwm Research Foundation, Inc. Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
IT202400001089A1 (it) * 2024-01-22 2025-07-22 Fondazione St Italiano Tecnologia Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093466A1 (en) 2007-10-03 2009-04-09 Bristol-Myers Squibb Company Carboxamide GABAa ALPHA2 Modulators
US20100004226A1 (en) 2004-06-30 2010-01-07 Cook James M Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20100317619A1 (en) 2002-03-28 2010-12-16 James Cook Selective Agents for Pain Suppression
US20150258128A1 (en) 2011-04-28 2015-09-17 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4226768A (en) 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20030176456A1 (en) 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
USRE47475E1 (en) 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US7595395B2 (en) * 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
US20100130479A1 (en) 2005-05-16 2010-05-27 Cook James M Gabaergic Agents to Treat Memory Deficits
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
DE102006023554A1 (de) 2006-05-19 2007-11-22 Zf Friedrichshafen Ag Ermittlung der Drehzahl einer Getriebewelle
US8923318B2 (en) 2008-10-02 2014-12-30 Telefonaktiebolaget L M Ericsson (Publ) Wireless communication system and method for assigning a channel in said wireless communication system
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317619A1 (en) 2002-03-28 2010-12-16 James Cook Selective Agents for Pain Suppression
US20100004226A1 (en) 2004-06-30 2010-01-07 Cook James M Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20090093466A1 (en) 2007-10-03 2009-04-09 Bristol-Myers Squibb Company Carboxamide GABAa ALPHA2 Modulators
US20150258128A1 (en) 2011-04-28 2015-09-17 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Namjoshi, Ojas A. et al ，Search for α3β2/3γ2 subtype selective ligands that are stable on human liver microsomes，Bioorganic & Medicinal Chemistry，2013年，21(1),，93-101
Poe, Michael M. et al，Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy，Journal of Medicinal Chemistry ，2016年，59(23),，10800-10806
REGISTRY（STN）[online]，2009年，CAS登録番号 1141017-14-2
Stamenic, Tamara Timic et al，Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit，European Journal of Pharmacology，2016年，791,，433-443

Also Published As

Publication number Publication date
AU2017235665A1 (en) 2018-09-27
HUE059774T2 (hu) 2023-01-28
US20250179080A1 (en) 2025-06-05
EP3439665A4 (en) 2019-11-27
EP3439665A1 (en) 2019-02-13
CA3016491A1 (en) 2017-09-21
JP2019509340A (ja) 2019-04-04
DK3439665T3 (da) 2022-09-26
EP4129297A1 (en) 2023-02-08
RS63674B1 (sr) 2022-11-30
PL3439665T3 (pl) 2023-01-16
US11753412B2 (en) 2023-09-12
ES2926918T3 (es) 2022-10-31
JP2022065035A (ja) 2022-04-26
US20240083905A1 (en) 2024-03-14
WO2017161370A1 (en) 2017-09-21
AU2022275446B2 (en) 2025-01-02
SI3439665T1 (sl) 2023-05-31
EP3439665B1 (en) 2022-06-29
SMT202200372T1 (it) 2022-11-18
US20210309662A1 (en) 2021-10-07
AU2017235665B2 (en) 2022-12-08
CY1125576T1 (el) 2026-02-25
LT3439665T (lt) 2022-10-10
WO2017161370A8 (en) 2018-09-27
US12180216B2 (en) 2024-12-31
AU2022275446A1 (en) 2023-01-05
US20200181146A1 (en) 2020-06-11
JP7515526B2 (ja) 2024-07-12
PT3439665T (pt) 2022-09-27
HRP20221098T1 (hr) 2022-11-25
US10906909B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
JP2022065035A (ja) α５含有ＧＡＢＡＡ受容体アゴニストによる神経変性および神経精神障害における認知症状および気分症状の処置
JP2022001573A (ja) 診断及び療法のための二環式化合物
AU2014368961B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN102711466A (zh) 桥连杂环化合物及其使用方法
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
US10259815B2 (en) Gabaergic ligands and their uses
KR20210054510A (ko) 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
US10975037B2 (en) Phenyl substituted pyrazoles as modulators of RORγt
BR112019018843A2 (pt) composto, processo para preparar compostos, composição farmacêutica, combinação, processo para fabricação de uma composição farmacêutica, e, método de tratamento e/ou prevenção de um distúrbio
CN114591352B (zh) 一种三唑并哒嗪类化合物及其应用
Epplin et al. Discovery of dihydropyrrolo [1, 2-a] pyrazin-3 (4H)-one-based second-generation GluN2C-and GluN2D-selective positive allosteric modulators (PAMs) of the N-methyl-d-aspartate (NMDA) receptor
US20240374612A1 (en) Imidazobenzodiazepines for treatment of cognitive and mood symptoms
JP6831376B2 (ja) トリアゾール誘導体
JP2021522290A (ja) １−イミダゾチアジアゾロ−２ｈ−ピロール−５−オン誘導体
TW201920079A (zh) 金剛烷基甲胺衍生物及其作為醫藥之使用
IL322951A (en) Hydroxyalkyl and methoxyalkyl-modified tryptamines
BR112019003065B1 (pt) Compostos moduladores do receptor gaba(a) ou sais farmaceuticamente aceitável dos mesmos, composição farmacêutica e forma de dosagem unitária compreendendo ditos compostos e usos terapêuticos dos mesmos
HK1230171B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220209

R150 Certificate of patent or registration of utility model

Ref document number: 7023876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250